Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Namrata Sen

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

Konskie,,Poland,-,February,24,,2024:,Sarepta,Therapeutics,Company,Logo

Shares of Sarepta Therapeutics (NASDAQ:SRPT) plunged over 30% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marking the third death linked to the company’s experimental treatments.

What Happened: Sarepta Therapeutics confirmed the death of a 51-year-old man who was part of a Phase 1 trial for a gene therapy aimed at treating limb-girdle muscular dystrophy, according to BioCentury. The patient died of liver failure last month after being administered the experimental treatment.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.